Gu-Jiun Lin

Dr. Gu-Jiun Lin

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GLGu-Jiun Lin
Gu-Jiun Lin
SHShing-Hwa Huang
Shing-Hwa Huang
Shyi-jou ChenShyi-jou Chen
Shyi-jou Chen
CWChih-Hung Wang
Chih-Hung Wang
DCDeh-Ming Chang
Deh-Ming Chang
HSHuey-Kang Sytwu
Huey-Kang Sytwu
Melatonin is the major secretory product of the pineal gland during the night and has multiple activities including the regulation of circadian and seasonal rhythms, and antioxidant and anti-inflammatory effects. It also possesses the ability to modulate immune responses by regulation of the T helper 1/2 balance and cytokine production. Autoimmune diseases, which result from the activation of immune cells by autoantigens released from normal tissues, affect around 5% of the population. Activation of autoantigen-specific immune cells leads to subsequent damage of target tissues by these activated cells. Melatonin therapy has been investigated in several animal models of autoimmune disease, where it has a beneficial effect in a number of models excepting rheumatoid arthritis, and has been evaluated in clinical autoimmune diseases including rheumatoid arthritis and ulcerative colitis. This review summarizes and highlights the role and the modulatory effects of melatonin in several inflammatory autoimmune diseases including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, and inflammatory bowel disease.

1 February 2016 in International Immunopharmacology
Verified
Journal Article
Closed access
SCShyi-Jou Chen
Shyi-Jou Chen
SHShing-Hwa Huang
Shing-Hwa Huang
JCJing-Wun Chen
Jing-Wun Chen
KWKai-Chen Wang
Kai-Chen Wang
YYYung-Rong Yang
Yung-Rong Yang
HSHuey-Kang Sytwu
Huey-Kang Sytwu

10 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
YLYi-Hsuan Lin
Yi-Hsuan Lin
YWYi-Hsun Wang
Yi-Hsun Wang
YPYi-Jen Peng
Yi-Jen Peng
FLFeng-Cheng Liu
Feng-Cheng Liu
GLGu-Jiun Lin
Gu-Jiun Lin
CCCHIA-PI CHENG
CHIA-PI CHENG
Interleukin 26 (IL-26) is a new member of the IL-10 family that is highly expressed in rheumatoid arthritis (RA). However, the functions of IL-26 produced by macrophages in RA have not been elucidated. In the present work, we evaluated the effects and the mechanisms of IL-26 on M1 and M2 macrophage differentiation. Human or mouse macrophage cells were treated with lipopolysaccharides (LPS), interferon gamma (IFNγ), or IL-4 alone or concurrently treated with IL-26 to monitor M1 or M2 macrophage subtypes. The expression level of M1 or M2 macrophage genes was evaluated by reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). The molecular mechanisms of downstream signaling activation during differentiation were investigated by immunoblotting assay. Our results found that IL-26 promoted macrophage cells from CD80+ M1 macrophage differentiation, not from the CD206+ M2 phenotype. The messenger RNA of M1-type macrophage markers tumor necrosis factor alpha (TNFα) and inducible nitric oxide synthase (iNOS) was up-regulated in the IL-26-treated group. Also, the M1-related proinflammatory cytokines TNFα and IL-6 were induced after IL-26 stimulation. Interestingly, IL-10, a cytokine marker of M2 macrophage, was also elevated after IL-26 stimulation. Moreover, the M1-like macrophage stimulated by IL-26 underwent cJUN, nuclear factor kappa B (NF-κB), and signal transducer and activator of transcription 1 (STAT1) activation. Our findings suggested the role of IL-26 in synovial macrophages of active rheumatoid arthritis and provided a new insight into IL-26 as a candidate therapeutic target in rheumatoid arthritis.

1 July 2009 in Oral Oncology
Verified
Journal Article
Closed access
YCYuan-Wu Chen
Yuan-Wu Chen
GLGu-Jiun Lin
Gu-Jiun Lin
WCWei-Tso Chia
Wei-Tso Chia
CLChih-Kung Lin
Chih-Kung Lin
YCYi-Ping Chuang
Yi-Ping Chuang
HSHuey-Kang Sytwu
Huey-Kang Sytwu

Verified
Journal Article
Open access
PDF file
Shyi-jou ChenShyi-jou Chen
Shyi-jou Chen
GLGu-Jiun Lin
Gu-Jiun Lin
JCJing-Wun Chen
Jing-Wun Chen
KWKai-Chen Wang
Kai-Chen Wang
CTChiung-Hsi Tien
Chiung-Hsi Tien
HSHuey-Kang Sytwu
Huey-Kang Sytwu
Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease of unknown etiology. It is characterized by the presence of rheumatoid factor and anticitrullinated peptide antibodies. The orchestra of the inflammatory process among various immune cells, cytokines, chemokines, proteases, matrix metalloproteinases (MMPs), and reactive oxidative stress play critical immunopathologic roles in the inflammatory cascade of the joint environment, leading to clinical impairment and RA. With the growing understanding of the immunopathogenic mechanisms, increasingly novel marked and potential biologic agents have merged for the treatment of RA in recent years. In this review, we focus on the current understanding of pathogenic mechanisms, highlight novel biologic disease-modifying antirheumatic drugs (DMRADs), targeted synthetic DMRADs, and immune-modulating agents, and identify the applicable immune-mediated therapeutic strategies of the near future. In conclusion, new therapeutic approaches are emerging through a better understanding of the immunopathophysiology of RA, which is improving disease outcomes better than ever.

1 July 2019 in Journal of Functional Foods
Verified
Journal Article
Open access
SHShing-Hwa Huang
Shing-Hwa Huang
CLChing-Len Liao
Ching-Len Liao
SCShyi-Jou Chen
Shyi-Jou Chen
LSLi-Ge Shi
Li-Ge Shi
LLLi Lin
Li Lin
GLGu-Jiun Lin
Gu-Jiun Lin